BR112014024230A8 - Polipeptídeo, derivado do polipeptídeo, ácido nucleico, vetor, célula hospedeira, método de produção do polipeptídeo, composição farmacêutica, kit, método de inibição de atividade de notch, método de tratamento de uma doença, anticorpo isolado, método de o aumento da atividade de notch - Google Patents
Polipeptídeo, derivado do polipeptídeo, ácido nucleico, vetor, célula hospedeira, método de produção do polipeptídeo, composição farmacêutica, kit, método de inibição de atividade de notch, método de tratamento de uma doença, anticorpo isolado, método de o aumento da atividade de notchInfo
- Publication number
- BR112014024230A8 BR112014024230A8 BR112014024230A BR112014024230A BR112014024230A8 BR 112014024230 A8 BR112014024230 A8 BR 112014024230A8 BR 112014024230 A BR112014024230 A BR 112014024230A BR 112014024230 A BR112014024230 A BR 112014024230A BR 112014024230 A8 BR112014024230 A8 BR 112014024230A8
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptide
- activity
- notch
- kit
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
- C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Insects & Arthropods (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
POLIPEPTÍDEO, DERIVADO DO POLIPEPTÍDEO, ÁCIDO NUCLEICO, VETOR, MÉTODO PARA OBTENÇÃO DE CÉLULA HOSPEDEIRA, MÉTODO DE PRODUÇÃO DO POLIPEPTÍDEO, COMPOSIÇÃO FARMACÊUTICA, KIT, USO DO POLIPEPTÍDEO, ANTICORPO MONOCLONAL ISOLADO, USO DO ANTICORPO. Trata-se de polipeptídeos e derivados dos mesmos que contêm sequências de urna proteína Serrate e que inibem função de trajetória de Notch. Também são fornecidos no presente documento ácidos nucleicos que codificam os polipeptídeos, vetores e células para a produção dos polipeptídeos e composições farmacêuticas e kits relacionados. Adicionalmente, são fornecidos anticorpos que se ligam à região inibitória de Notch de urna proteína Serrate. Também são fornecidos métodos terapêuticos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2012/031213 WO2013147793A1 (en) | 2012-03-29 | 2012-03-29 | Methods and compositions for modulating notch activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014024230A2 BR112014024230A2 (pt) | 2017-06-20 |
| BR112014024230A8 true BR112014024230A8 (pt) | 2017-07-25 |
Family
ID=49260857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014024230A BR112014024230A8 (pt) | 2012-03-29 | 2012-03-29 | Polipeptídeo, derivado do polipeptídeo, ácido nucleico, vetor, célula hospedeira, método de produção do polipeptídeo, composição farmacêutica, kit, método de inibição de atividade de notch, método de tratamento de uma doença, anticorpo isolado, método de o aumento da atividade de notch |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150291681A1 (pt) |
| KR (1) | KR20150014439A (pt) |
| AU (1) | AU2012375337A1 (pt) |
| BR (1) | BR112014024230A8 (pt) |
| CA (1) | CA2868747A1 (pt) |
| CL (1) | CL2014002596A1 (pt) |
| EC (1) | ECSP14024753A (pt) |
| MX (1) | MX2014011608A (pt) |
| PH (1) | PH12014502182A1 (pt) |
| WO (1) | WO2013147793A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013278075B2 (en) | 2012-06-22 | 2018-05-17 | Cytomx Therapeutics, Inc. | Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof |
| CN111269311B (zh) * | 2019-09-30 | 2023-10-13 | 复旦大学 | 一种增强型合成Notch受体及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997001571A1 (en) * | 1995-06-28 | 1997-01-16 | Imperial Cancer Research Technology, Ltd. | Nucleotide and protein sequences of vertebrate delta genes and methods based thereon |
| WO2004082710A1 (en) * | 2003-03-21 | 2004-09-30 | Lorantis Limited | Treatment of allergic diseases using a modulator of the notch signaling pathway |
-
2012
- 2012-03-29 CA CA2868747A patent/CA2868747A1/en not_active Abandoned
- 2012-03-29 MX MX2014011608A patent/MX2014011608A/es unknown
- 2012-03-29 US US14/388,598 patent/US20150291681A1/en not_active Abandoned
- 2012-03-29 BR BR112014024230A patent/BR112014024230A8/pt not_active IP Right Cessation
- 2012-03-29 WO PCT/US2012/031213 patent/WO2013147793A1/en active Application Filing
- 2012-03-29 AU AU2012375337A patent/AU2012375337A1/en not_active Abandoned
- 2012-03-29 KR KR1020147030124A patent/KR20150014439A/ko not_active Application Discontinuation
-
2014
- 2014-09-29 CL CL2014002596A patent/CL2014002596A1/es unknown
- 2014-09-29 PH PH12014502182A patent/PH12014502182A1/en unknown
- 2014-10-28 EC ECIEPI201424753A patent/ECSP14024753A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014024230A2 (pt) | 2017-06-20 |
| US20150291681A1 (en) | 2015-10-15 |
| ECSP14024753A (es) | 2015-09-30 |
| MX2014011608A (es) | 2015-05-11 |
| CA2868747A1 (en) | 2013-10-03 |
| PH12014502182A1 (en) | 2014-12-10 |
| KR20150014439A (ko) | 2015-02-06 |
| WO2013147793A1 (en) | 2013-10-03 |
| AU2012375337A1 (en) | 2014-10-16 |
| CL2014002596A1 (es) | 2015-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017010110A2 (pt) | anticorpos contra cd73 e usos do mesmo | |
| MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
| BR122020002402B8 (pt) | Proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, célula hospedeira recombinante, métodos de confecção da referida proteína de ligação e uso da mesma | |
| CY1123028T1 (el) | Σταθερα και διαλυτα αντισωματα που αναστελλουν τον vegf | |
| AR127516A2 (es) | VARIANTES DE Fc Y MÉTODOS PARA SU PRODUCCIÓN | |
| BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
| BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| BR112017025564A2 (pt) | anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
| EA201792047A1 (ru) | Новые соединения | |
| BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
| BR112018005573A2 (pt) | ?polipeptídeos de ligação a cd3? | |
| BR112014008694A2 (pt) | moléculas de ácido nucleico policistrônico recombinante | |
| BR112016014810A2 (pt) | Antagonistas de fcrn e métodos de uso | |
| UA115657C2 (uk) | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла | |
| AR092818A1 (es) | Anticuerpo tau humanizado | |
| BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
| AR090047A1 (es) | Dominio variable dual de inmunoglobulinas y sus usos | |
| BR112012025568A2 (pt) | proteínas de ligação ao tnf-<244>. | |
| EA201491644A1 (ru) | Фармацевтические композиции | |
| BR112014024282A2 (pt) | anticorpos ligantes ao receptor b1 da bradicinina | |
| BR112017023646A2 (pt) | proteínas agonistas de receptor de cd40 de cadeia simples | |
| BR112017006598A2 (pt) | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) | |
| EA201690377A1 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| BR112015029953A2 (pt) | anticorpos anti-tweakr e seus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |